Samsrita Labs Ltd. is an India-based company. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-08-10. The firm is engaged activities, such as trading, exports and imports, manufacturing of bulk drugs, APIs, Specialty drugs, research and development (R&D) through joint ventures or associations or mergers or by its own. The company has established platforms in the areas of stem cell research and therapy, new drug discovery, molecular prognosis and diagnostics services, CRO, stem cell focused super specialty hospital, RNA interference technology and medical devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology, stem cell and cord blood banking. Its New Drug Discovery division is focused on working on five therapeutic areas of Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular diseases, cystinosis and Huntington's disease.
Loading chart…
This company hasn't held an earnings call in the last six months, so there's no recent commentary from management. Our deep dives are built on what management actually said, so we haven't prepared one.
18 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.